Gene Differential Expression with Hotspot Mutation
In this panel, you can compare gene/signature expression level between patients with and without key hotspot mutations.
GEPIA performs ANOVA or Wilcoxon rank-sum test for differential expression analysis with hotspot mutation. Only significant results will be provided (p < 0.1). Meanwhile, you can compare expression correlation between your query gene and hotspot gene in mutant or non-mutant cases by click 'plot' button. Spearman's r was used in Correlation analysis. Only primary tumor expression level was included in this function. The criteria for hotspot mutations are mutation frequency > 0.05 and occurrence in at least 10 samples.
Parameters:
- Gene: Input a gene/isoform or gene signature A of interest.
- Methods: Select ANOVA or Wilcoxon for differential analysis.
- log2 transformed: Select whether use log2(TPM+1) as expression abundance.
- Hotspot Mutation Type: Select the type of mutation. Gene level means any nonsilent mutation in the gene. Amino acid level means changes at specific amino acid site (HGSV protein-level).
- Datasets Selection: Select one or multiple cancer types of interest in the "Dataset Selection" field and click "add" to build dataset list in the "Datasets" field.
- Plot Color: Choose group color to plot differential expression boxplot and correlation scatter plot.
Results:
- The table shows the significant results of differential expression between hotspot mutant and wildtype cases. Click the button beside mutation to plot gene/signature expression distribution of mutant and wildtype groups, as well as the expression correlation with the hotspot gene.
TCGA Abbr.
Abbr | Detail |
---|---|
ACC | Adrenocortical carcinoma |
BLCA | Bladder Urothelial Carcinoma |
BRCA | Breast invasive carcinoma |
CESC | Cervical squamous cell carcinoma and endocervical adenocarcinoma |
CHOL | Cholangiocarcinoma |
COAD | Colon adenocarcinoma |
DLBC | Lymphoid Neoplasm Diffuse Large B-cell Lymphoma |
ESCA | Esophageal carcinoma |
GBM | Glioblastoma multiforme |
HNSC | Head and Neck squamous cell carcinoma |
KICH | Kidney Chromophobe |
KIRC | Kidney renal clear cell carcinoma |
KIRP | Kidney renal papillary cell carcinoma |
LAML | Acute Myeloid Leukemia |
LGG | Brain Lower Grade Glioma |
LIHC | Liver hepatocellular carcinoma |
LUAD | Lung adenocarcinoma |
LUSC | Lung squamous cell carcinoma |
MESO | Mesothelioma |
OV | Ovarian serous cystadenocarcinoma |
PAAD | Pancreatic adenocarcinoma |
PCPG | Pheochromocytoma and Paraganglioma |
PRAD | Prostate adenocarcinoma |
READ | Rectum adenocarcinoma |
SARC | Sarcoma |
SKCM | Skin Cutaneous Melanoma |
STAD | Stomach adenocarcinoma |
TGCT | Testicular Germ Cell Tumors |
THCA | Thyroid carcinoma |
THYM | Thymoma |
UCEC | Uterine Corpus Endometrial Carcinoma |
UCS | Uterine Carcinosarcoma |
UVM | Uveal Melanoma |
License Statement: All content on this website is freely available to all users, including for commercial use.